Protagonist Therapeutics (PTGX) Competitors $45.80 -1.15 (-2.45%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. RDY, MRNA, VTRS, QGEN, ASND, ROIV, LNTH, TGTX, RVMD, and BBIOShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Lantheus (LNTH), TG Therapeutics (TGTX), Revolution Medicines (RVMD), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Dr. Reddy's Laboratories Moderna Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Lantheus TG Therapeutics Revolution Medicines BridgeBio Pharma Protagonist Therapeutics (NASDAQ:PTGX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking. Do analysts rate PTGX or RDY? Protagonist Therapeutics presently has a consensus price target of $65.44, suggesting a potential upside of 42.89%. Dr. Reddy's Laboratories has a consensus price target of $17.00, suggesting a potential upside of 26.58%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Protagonist Therapeutics is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher earnings & valuation, PTGX or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$434.43M6.47-$78.96M$4.2010.90Dr. Reddy's Laboratories$311.31B0.04$668M$0.6321.32 Is PTGX or RDY more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Dr. Reddy's Laboratories' net margin of 17.25%. Protagonist Therapeutics' return on equity of 34.68% beat Dr. Reddy's Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics52.76% 34.68% 30.98% Dr. Reddy's Laboratories 17.25%17.87%12.32% Which has more volatility & risk, PTGX or RDY? Protagonist Therapeutics has a beta of 2.3, meaning that its share price is 130% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Does the MarketBeat Community favor PTGX or RDY? Dr. Reddy's Laboratories received 30 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. However, 61.65% of users gave Protagonist Therapeutics an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformProtagonist TherapeuticsOutperform Votes29161.65% Underperform Votes18138.35% Dr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% Do insiders and institutionals hold more shares of PTGX or RDY? 98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 5.4% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor PTGX or RDY? In the previous week, Dr. Reddy's Laboratories had 4 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 13 mentions for Dr. Reddy's Laboratories and 9 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.20 beat Dr. Reddy's Laboratories' score of 0.71 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive SummaryProtagonist Therapeutics beats Dr. Reddy's Laboratories on 14 of the 19 factors compared between the two stocks. Remove Ads Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.81B$6.26B$5.29B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio17.226.6921.6517.68Price / Sales6.47222.70371.0992.89Price / CashN/A65.6738.1534.64Price / Book7.845.776.373.94Net Income-$78.96M$142.01M$3.20B$247.45M7 Day Performance7.59%2.88%1.79%0.48%1 Month Performance-16.39%-13.93%-9.41%-7.08%1 Year Performance75.41%-12.36%9.61%-0.35% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics3.7693 of 5 stars$45.80-2.4%$65.44+42.9%+76.6%$2.81B$434.43M17.22120News CoveragePositive NewsRDYDr. Reddy's Laboratories3.2081 of 5 stars$12.59+1.8%$17.00+35.1%-6.3%$10.51B$311.31B20.0424,800Positive NewsHigh Trading VolumeMRNAModerna4.242 of 5 stars$25.64+2.1%$59.00+130.1%-74.7%$9.91B$3.20B-2.763,900VTRSViatris2.978 of 5 stars$7.61-0.1%$10.50+38.0%-33.9%$9.08B$14.74B-10.2837,000News CoverageHigh Trading VolumeQGENQiagen3.3695 of 5 stars$40.33+5.4%$47.71+18.3%+7.7%$8.96B$1.98B112.296,030News CoverageHigh Trading VolumeASNDAscendis Pharma A/S3.1115 of 5 stars$140.14-1.8%$204.64+46.0%+6.0%$8.50B$363.64M-19.741,017Analyst ForecastPositive NewsGap DownROIVRoivant Sciences2.6385 of 5 stars$9.26-2.1%$17.50+89.0%-7.2%$6.61B$122.59M-61.73860Positive NewsGap UpHigh Trading VolumeLNTHLantheus4.3452 of 5 stars$95.45+5.0%$129.43+35.6%+70.6%$6.54B$1.53B15.88700Positive NewsTGTXTG Therapeutics3.3355 of 5 stars$37.25-0.3%$40.67+9.2%+177.4%$5.85B$329.00M-372.46290Positive NewsRVMDRevolution Medicines3.722 of 5 stars$31.40+0.3%$65.23+107.7%+2.2%$5.84B$742,000.00-8.75250Positive NewsHigh Trading VolumeBBIOBridgeBio Pharma4.5666 of 5 stars$30.67-2.2%$52.64+71.6%+32.9%$5.83B$221.90M-10.76400Analyst ForecastInsider TradeAnalyst RevisionPositive News Remove Ads Related Companies and Tools Related Companies Dr. Reddy's Laboratories Alternatives Moderna Alternatives Viatris Alternatives Qiagen Alternatives Ascendis Pharma A/S Alternatives Roivant Sciences Alternatives Lantheus Alternatives TG Therapeutics Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
